Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pertuzumab (HLX29 vs HLX11) PK Study in Healthy Males
NCT07776132Phase 1Not yet recruiting
- Sponsor
- Henlius
- Start
- Nov 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of pertuzumab in breast cancer (2 arms), sponsored by Henlius. Primary endpoint: Area under the plasma concentration-time curve from time zero to infinity up to 71 days. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
pertuzumab
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07776132.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07776132.